Skip to main content

Advertisement

Log in

When should we use parenteral methotrexate?

Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Oral methotrexate is the benchmark against which other disease-modifying anti rheumatic drugs are measured. The use of parenteral methotrexate for those failing to tolerate or respond to oral therapy is accepted, but indications for its use and its place in the therapeutic ladder have not been fully investigated. We assessed the use of parenteral methotrexate (MTX) in our rheumatoid arthritis (RA) population and compared the characteristics of these patients to a matched group of those on oral therapy. We compared response rates to each approach using DAS 28 scores, ESR and visual analogue scales. Inferences on costs of parenteral therapy were made and predictors of response defined. We found that 10% of our total RA patient population were on parenteral methotrexate, having failed to tolerate or respond to oral therapy. Seventy-five percent of these met the criteria for the use of anti-tumour necrosis factor (TNF) agents. Overall response rates were equivalent to those obtained by responders to oral MTX. Patients on parenteral therapy were younger and were more likely to have extreme values of body mass index (BMI) than those on oral therapy. The approach was economically viable, although many patients unnecessarily attended hospital to receive their injections. We advocate consideration of parenteral MTX in all RA patients unresponsive to oral therapy prior to treatment with anti-TNF therapy. Response to parenteral therapy can be predicted by low BMI (below 22 kg/m2), possibly as a result of malabsorption, or by high BMI (over 30) as a result of gastrointestinal intolerance. A mechanism to deliver this option through self-administration in the community should be encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Weinblatt M, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC et al (1994) Methotrexate in rheumatoid arthritis: a five year prospective multicenter study. Arthritis Rheum 37:1492–1498

    Article  CAS  PubMed  Google Scholar 

  2. Kremer JM (1997) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 40:984–985

    Article  CAS  PubMed  Google Scholar 

  3. Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 29:1631–1638

    CAS  PubMed  Google Scholar 

  4. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 44:61–66

    Article  CAS  PubMed  Google Scholar 

  5. Furst DE, Keystone EC, Kirkham B, Fleischman R, Mease P, Breedveld FC et al (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 67:ii2–iii25

    Article  Google Scholar 

  6. American College of Rheumatology (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328–346

    Article  Google Scholar 

  7. Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology 41:1367–1374

    Article  CAS  PubMed  Google Scholar 

  8. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ (2002) Homocysteine and folate status in methotrexate treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41:658–665

    Article  Google Scholar 

  9. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Laar M (2006) Splitting high-dose oral methotrexate improves bioavalability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 33:481–485

    CAS  PubMed  Google Scholar 

  10. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kremer JR et al (2007) Obesity increases oesophageal acid exposure. Gut 56:749–755

    Article  PubMed  Google Scholar 

  11. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V (2004) Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 50:364–371

    Article  CAS  PubMed  Google Scholar 

  12. Braun J, Kastner P, Flaxenburg P, Wahrisch J, Hanke P, Demary W et al (2008) Comparison of the clinical efficacy and safety of subcutaneous methotrexate in patients with active rheumatoid arthritis: results of a six month multicenter randomized double blind controlled phase IV trial. Arthritis Rheum 58:73–81

    Article  CAS  PubMed  Google Scholar 

  13. Kremer JM, Hamilton RA (1997) Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol 36:86–90

    Article  Google Scholar 

  14. Collins K, Aspey H, Todd A, Rynne M, Saravanan V, Kelly CA (2008) Methotrexate pneumonitis precipitated by switching from oral to subcutaneous administration. Rheumatology 47:109–110

    Article  CAS  PubMed  Google Scholar 

  15. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31:645–648

    CAS  PubMed  Google Scholar 

  16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  CAS  PubMed  Google Scholar 

  17. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432

    Article  PubMed  Google Scholar 

  18. Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW et al (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423–426

    Article  CAS  PubMed  Google Scholar 

  19. Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43:22–29

    Article  CAS  PubMed  Google Scholar 

  20. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56:1765–1775

    Article  CAS  PubMed  Google Scholar 

  21. Hider SL, Silman AJ, Thomson W, Lunt M, Bunn D, Symmons DPM (2009) Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 58:57–62

    Google Scholar 

  22. Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P et al (2003) Relationship between body mass and gastro-oesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol 32:645–650

    Article  PubMed  Google Scholar 

  23. Cronstein BN (1996) Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 39:1951–1960

    Article  CAS  PubMed  Google Scholar 

  24. Ranganathan P, McLeod HL (2006) Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366–1377

    Article  CAS  PubMed  Google Scholar 

  25. Criswell LA, Lum RF, Turner KN, Peden EA, Means GD, Derry MJ et al (2002) The HLA-DRB1 shared epitope as a predictor of response to treatment of RA with methotrexate and etanercept. Arthritis Rheum 46(Suppl):376

    Google Scholar 

  26. Lee YC, Cui J, Costenbader JH, Shadick NA, Weinblatt ME, Karlson EW (2009) Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 48:613–617

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Clive Kelly.

Additional information

No source of funding was given to support this study.

We agree to Clinical Rheumatology having the licence to publish this paper and confirm that it is not under consideration by any other journal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mainman, H., McClaren, E., Heycock, C. et al. When should we use parenteral methotrexate?. Clin Rheumatol 29, 1093–1098 (2010). https://doi.org/10.1007/s10067-010-1500-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1500-9

Keywords

Navigation